Yonsei Med J. 1994 Mar;35(1):91-96. English.
Published online Feb 20, 2002.
https://doi.org/10.3349/ymj.1994.35.1.91
Published online Feb 20, 2002.
https://doi.org/10.3349/ymj.1994.35.1.91
Copyright © 1994 The Yonsei University College of Medicine
Case Report
GM-CSF and low-dose araC treatment of AML in prolonged hypoplasia with residual leukemic cells after induction chemotherapy
Yoo Hong Min,
Sung Eun Kim,
Seung Tae Lee,
Sun Ju Lee,
Jee Sook Hahn
and Yun Woong Ko
Abstract
We describe a case with acute myelogenous leukemia (AML; M2) who developed prolonged marrow hypoplasia with residual leukemic blasts and recurrent infections after induction chemotherapy. He was treated successfully with a sequential treatment of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and low-dose cytosine arabinoside (LD AraC). To the best of our knowledge this is the first reported case of a successful treatment of a patient with AML, who showed prolonged markedly hypocellular bone marrow with significant residual leukemic cells after induction chemotherapy, with a sequential treatment of GM-CSF and LD AraC.
Keywords
Acute myelogenous leukemia GM-CSF; low-dose Ara-C
Cited by
MeSH Terms
Permalink information copied to clipboard